Transplantation of bone marrow-derived stem cells: A promising therapy for stroke

Yamei Tang, Takao Yasuhara, Koichi Hara, Noriyuki Matsukawa, Mina Maki, Guolong Yu, Lin Xu, David C. Hess, Cesario V. Borlongan

Research output: Contribution to journalArticlepeer-review

98 Scopus citations


Stroke remains a major cause of death in the US and around the world. Over the last decade, stem cell therapy has been introduced as an experimental treatment for stroke. Transplantation of stem cells or progenitors into the injured site to replace the nonfunctional cells, and enhancement of proliferation or differentiation of endogenous stem or progenitor cells stand as the two major cell-based strategies. Potential sources of stem/progenitor cells for stroke include fetal neural stem cells, embryonic stem cells, neuroteratocarcinoma cells, umbilical cord blood-derived nonhematopoietic stem cells, and bone marrow-derived stem cells. The goal of this article is to provide an update on the preclinical use of bone marrow-derived stem cells with major emphasis on mesenchymal stem cells (MSCs) and multipotent adult progenitor cells (MAPCs) because they are currently most widely applied in experimental stroke studies and are now being phased into early clinical trials. The phenotypic features of MSCs and MAPCs, as well as their application in stroke, are described.

Original languageEnglish (US)
Pages (from-to)159-169
Number of pages11
JournalCell Transplantation
Issue number2
StatePublished - 2007


  • Neural repair
  • Neurological disorder
  • Neurotrophic factor
  • Progenitor cell

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Transplantation of bone marrow-derived stem cells: A promising therapy for stroke'. Together they form a unique fingerprint.

Cite this